Predictors of early-stage left ventricular dysfunction in type 2 diabetes: Results of DYDA study

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 18, Issue 3, 2011, Pages 415-423

  Giorda, Carlo B ^a   Cioffi, Giovanni ^b   De Simone, Giovanni ^c   Di Lenarda, Andrea ^d   Faggiano, Pompilio ^e   Latini, Roberto ^f   Lucci, Donata ^g   Maggioni, Aldo P ^g   Tarantini, Luigi ^h   Velussi, Mario ⁱ   Verdecchia, Paolo ^j   Comaschi, Marco ^k  

^a ASL Torino 5   (Italy)

^b Villa Bianca Hospital   (Italy)

^c FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^d Cardiovascular Unit   (Italy)

^e SPEDALI CIVILI   (Italy)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^g ANMCO RESEARCH CENTER   (Italy)

^h SAN MARTINO HOSPITAL   (Italy)

ⁱ Diabetology Department   (Italy)

^j Assisi Hospital   (Italy)

^k UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

Early stage left ventricular dysfunction; Predictive factors; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ALDOSTERONE ANTAGONIST; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; LIVER ENZYME; METFORMIN; REPAGLINIDE; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; DIASTOLIC DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC DYSFUNCTION;

AGED; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCIDENCE; INSULIN RESISTANCE; ITALY; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 79959187619     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/1741826710389402     Document Type: Article

References (26)

1. Kannel WB, Hjortland M and Castelli WP. Role of diabetes in congestive heart failure: the Framingham Study. Am J Cardiol 1974; 34: 29-34.
2. Thrainsdottir IS, Aspelund T, Hardarson T, Malmberg K, Sigurdsson G, Thorgeirsson G, et al. Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavík Study. Eur J Cardiovasc Prev Rehabil 2005; 12: 465-471. (Pubitemid 44966791)
3. Clarke P, Gray A, Legood R, Briggs A and Holman R. The impact of diabetes-related complications on healthcare costs: results from the UK Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003; 20: 442-450.
4. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC and Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003; 108(8): 977-982. (Pubitemid 37048228)
5. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al.; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
6. Cioffi G, Giorda CB, Chinali M, Di Lenarda A, Faggiano P, Lucci D, et al. Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. Eur J Cardiovasc Prev Rehabil 2010, under review.
7. The AMD Annals 2009 Working Group. Longitudinal analysis of quality indicators of diabetes care in Italy (2004-2007). Associazione Medici Diabetologi (AMD), Rome 2009.
8. Davies M, Hobbs F, Davis R, Kenkre J, Roalfe AK, Hare R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001; 358: 439-444. (Pubitemid 32769849)
9. Raymond I, Pedersen F, Steensgaard-Hansen F, Green A, Busch-Sorensen M, Tuxen C, et al. Prevalence of impaired left ventricular systolic function and heart failure in a middle aged and elderly urban population segment of Copenhagen. Heart 2003; 89: 1422-1429. (Pubitemid 37465240)
10. Cacciapuoti F, Marfella R, Paolisso G and Cacciapuoti F. Is the aging heart similar to the diabetic heart? Evaluation of LV function of the aging heart with tissue doppler imaging. Aging Clin Exp Res 2009; 21: 22-26.
11. Goode KM, John J, Rigby AS, Kilpatrick ES, Atkin SL, Bragadeesh T, et al. Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart 2009; 95: 917-923.
12. Hirai J, Ueda K, Takegoshi T and Mabuchi H. Effects of metabolic control on ventricular function in type 2 diabetic patients. Intern Med 1992; 31: 725-730.
13. Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B, et al.; CHARM Program Investigators. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008; 168: 1699-1704.
14. Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 2007; 30: 1241-1247. (Pubitemid 46684654)
15. Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, et al.; DAI Study Group. Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke 2007; 38: 1154-1160.
16. Fang ZY, Schull-Meade R, Downey M, Prins J and Marwick TH. Determinants of subclinical diabetic heart disease. Diabetologia 2005; 48: 394-402. (Pubitemid 40543314)
17. Roberts F and Ryan GJ. The safety of metformin in heart failure. Ann Pharmacother 2007; 41: 642-646. (Pubitemid 46625487)
18. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007; 335: 497.
19. Ren J, Dominguez LJ, Sowers JR and Davidoff AJ. Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in adult rat ventricular myocytes. Diabetes 1999; 48: 2059-2065. (Pubitemid 29458372)
20. Mamdani M, Sykora K, Li P, Notmand TS-L, Steiner LD, Austin CP, et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 2005; 330: 960-962.
21. Holman RR, Paul SK, Bethel MA, Matthews DR and Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
22. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003; 42: 239-246.
23. Wang CH, Weisel RD, Liu PP, Fedak PW and Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003; 107: 1350-1354. (Pubitemid 36350730)
24. Yamamoto K, Ohki R, Lee RT, Ikeda U and Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 2001; 104: 1670-1675. (Pubitemid 32947532)
25. Ozasa N, Furukawa Y, Tadamura E, Kita T and Kimura T. Relation among left ventricular mass, insulin resistance, and hemodynamic parameters in type 2 diabetes. Hypertens Res 2008; 31: 425-432. (Pubitemid 351597495)
26. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-2159.